BRPI0507325A - antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia - Google Patents

antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia

Info

Publication number
BRPI0507325A
BRPI0507325A BRPI0507325-1A BRPI0507325A BRPI0507325A BR PI0507325 A BRPI0507325 A BR PI0507325A BR PI0507325 A BRPI0507325 A BR PI0507325A BR PI0507325 A BRPI0507325 A BR PI0507325A
Authority
BR
Brazil
Prior art keywords
anesthesia
receptor antagonists
improve recovery
recovery
improve
Prior art date
Application number
BRPI0507325-1A
Other languages
English (en)
Inventor
Mary Anne Hickman
Christine Edna Miskell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0507325A publication Critical patent/BRPI0507325A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"ANTANISTAS DOS RECEPTORES NK-1 PARA MELHORAR A RECUPERAçãO DA ANESTESIA". A presente invenção refere-se à administração de composto das fórmulas (I) e (La), no qual R¬2¬ é selecionado a partir de um grupo consistindo em metila, etila, isopropila, sec-butila e terc-butila, a um animal para melhorar a recuperação da anestesia.
BRPI0507325-1A 2004-01-30 2005-01-06 antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia BRPI0507325A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54069704P 2004-01-30 2004-01-30
PCT/IB2005/000010 WO2005082366A1 (en) 2004-01-30 2005-01-06 Nk-1 receptor antagonists anesthesia recovery

Publications (1)

Publication Number Publication Date
BRPI0507325A true BRPI0507325A (pt) 2007-07-03

Family

ID=34910695

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507325-1A BRPI0507325A (pt) 2004-01-30 2005-01-06 antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia

Country Status (14)

Country Link
US (1) US20070155782A1 (pt)
EP (1) EP1713479A1 (pt)
JP (1) JP2007519701A (pt)
KR (1) KR100880391B1 (pt)
CN (1) CN1913893A (pt)
AU (1) AU2005216706B2 (pt)
BR (1) BRPI0507325A (pt)
CA (1) CA2554823A1 (pt)
IL (1) IL176830A0 (pt)
MX (1) MXPA06007964A (pt)
NO (1) NO20062965L (pt)
RU (1) RU2337685C2 (pt)
WO (1) WO2005082366A1 (pt)
ZA (1) ZA200605149B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034099T2 (en) 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
RU2489765C1 (ru) * 2012-01-10 2013-08-10 Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") Способ изготовления газонаполненного разрядника
CN114984223B (zh) * 2022-05-31 2023-06-20 中国人民解放军陆军军医大学第二附属医院 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用
AT527172A1 (de) * 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung
WO2026099213A1 (fr) * 2024-11-05 2026-05-15 Ceva Sante Animale Compositions comprenant du maropitant base et leurs utilisations
FR3168163A1 (fr) * 2024-11-05 2026-05-08 Ceva Sante Animale Compositions aqueuses comprenant du maropitant et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US540897A (en) 1895-06-11 Harold f
US540644A (en) 1895-06-11 del yalle
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
EP1411946A1 (en) * 2001-07-20 2004-04-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses

Also Published As

Publication number Publication date
WO2005082366A1 (en) 2005-09-09
AU2005216706A1 (en) 2005-09-09
EP1713479A1 (en) 2006-10-25
MXPA06007964A (es) 2007-01-26
WO2005082366A8 (en) 2005-12-15
IL176830A0 (en) 2006-10-31
KR100880391B1 (ko) 2009-01-30
US20070155782A1 (en) 2007-07-05
NO20062965L (no) 2006-07-21
ZA200605149B (en) 2007-11-28
RU2006126828A (ru) 2008-03-10
JP2007519701A (ja) 2007-07-19
RU2337685C2 (ru) 2008-11-10
AU2005216706B2 (en) 2007-11-29
CA2554823A1 (en) 2005-09-09
KR20060127934A (ko) 2006-12-13
CN1913893A (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
NO20042811L (no) Substituerte henzoksazoler og analoger som estrogene midler
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
EP1939175A4 (en) SULFONAMIDE DERIVATIVITY WITH PGD2 RECEPTOR ANTAGONISTIC EFFECT
BRPI0415449A (pt) combinações de compostos ativos fungicidas sinergìsticos
GT200400277A (es) Procedimiento de preparacion
HRP20010514B1 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
MA31988B1 (fr) Derives d'aminopyrazole
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
WO2003030937A1 (en) Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
SE0302760D0 (sv) New compounds
WO2006037047A3 (en) The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
BR0214224A (pt) Derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5h-1-benzazepina ou sal do mesmo
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
BRPI0511532A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para a terapia de distúrbios gastrointestinais funcionais e de sìndrome do intestino irritável em um animal de sangue quente, e para a preparação de um composto
TW200505823A (en) CaSR antagonist
WO2008008718A3 (en) Cyclopentane derivatives as antiglaucoma agents
NO20013684L (no) Substituerte fenetylaminderivater
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
NO20013060L (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
BR0317487A (pt) O r-isÈmero de compostos de aminoácido beta como derivados de antagonistas de receptores de integrina
BRPI0408204A (pt) derivados de quinolinona/benzoxazinona e usos dos mesmos
DE60324685D1 (de) 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.